Ocular cicatricial pemphigoid

Area of Science:

• Ophthalmology
• Immunology
• Dermatology

Background:

• Ocular cicatricial pemphigoid (OCP) is characterized by progressive conjunctival shrinkage.
• OCP can involve cutaneous and oral mucosal tissues, affecting 21% and 50% of patients, respectively.
• Pathological findings include immunoglobulin and complement deposition in conjunctival epithelium and basement membrane.

Purpose of the Study:

• To investigate the clinical features, immunological markers, and progression of ocular cicatricial pemphigoid.
• To identify associations between OCP and specific HLA types.
• To evaluate the impact of treatment on disease progression.

Main Methods:

• Analysis of clinical data from 78 OCP patients.
• Immunofluorescence studies to detect antibody and complement deposition.
• HLA typing to assess genetic associations.
• Clinical follow-up averaging 22 months.

Main Results:

• Conjunctival shrinkage is the hallmark of OCP.
• Circulating antibodies targeting conjunctival and corneal epithelium were identified.
• An increased prevalence of HLA-B12 was observed in OCP patients.
• Patients untreated with immunosuppressives or corticosteroids showed disease progression, though the course is variable.

Conclusions:

• OCP involves complex immunological mechanisms with characteristic autoantibody profiles.
• HLA-B12 may be a predisposing genetic factor for OCP.
• Systemic corticosteroids can suppress acute manifestations and potentially slow conjunctival shrinkage.